Posts

Posted on

IHOP® Announces 2021 Kid Chef and Adds Winning Pancake to Menus Nationwide to Benefit Children’s Miracle Network Hospitals and Other Causes

IHOP® Announces 2021 Kid Chef and Adds Winning Pancake to Menus Nationwide to Benefit Children’s Miracle Network Hospitals and Other Causes

Kid Chef Rayaan named IHOP 2021 Kid Chef with proceeds from his winning Caramel Apple a la Mode Pancake Benefitting Children’s Causes

GLENDALE, Calif.–(BUSINESS WIRE)–
Today, IHOP® named Rayaan, 8, of Orange County, Calif. as the 2021 IHOP Kid Chef Champion. The third-annual Kid Chef contest invited pediatric patients ages 6-16 from any Children’s Miracle Network Hospital to unleash their culinary creativity and concoct a new pancake recipe. Rayaan earned the 2021 chef’s coat with his Caramel Apple a la Mode pancake recipe: two fluffy buttermilk pancakes topped with warm, cinnamon-spiced apples, drizzled with caramel sauce, and crowned with one scoop of premium vanilla ice cream.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005460/en/

Kid Chef Winner, Rayaan (Photo: Business Wire)

Kid Chef Winner, Rayaan (Photo: Business Wire)

“My mom makes the best apple pie ever!” said Rayaan. The Caramel Apple a la Mode creation pairs his apple pie affinity with pancakes, an unexpected favorite tool in his treatment journey. Diagnosed with a rare autoimmune disorder, resultant in coma and life support, Rayaan ultimately relearned how to chew, eat, and swallow on his own using pancakes as his practice food.

To celebrate his journey, IHOP is featuring these special pancakes on menus for guests to enjoy nationwide for a good cause where $1 from every Caramel Apple a la Mode pancake full stack or combo ordered benefits Children’s Miracle Network Hospitals or The Leukemia & Lymphoma Society. Donations from pancake sales fund critical life-saving treatments and healthcare services, along with innovative research, vital pediatric medical equipment, and child life services that put kids and families’ minds at ease during difficult hospital stays. Rayaan’s winning pancake stack is available for dine-in only at participating IHOP restaurants from September 13-October 31, 2021*.

“We are thrilled to crown Rayaan with this year’s coveted Kid Chef title and welcome guests to sample his pancake masterpiece,” said Jay Johns, President of IHOP. “For more than 60 years, IHOP has committed to serve its communities in fun, engaging ways that bring joy and smiles to guests of all ages.”

“Our local children’s hospitals need help now more than ever,” said Teri Nestel, president and CEO of Children’s Miracle Network Hospitals. “IHOP’s pancake-stack fundraising campaign with Kid Chef Rayaan makes it easy for everyone to give back, while enjoying a delicious treat created by a kid. When added together, these funds provide major support for our local children’s hospitals to improve treatments and facilities, advance pioneering research and provide patient services now and what’s ahead. When we change kids’ health, we change the future – for all of us.”

Over the past 15 years, IHOP has raised more than $30 million for its portfolio of charity partners, including Children’s Miracle Network Hospitals and The Leukemia & Lymphoma Society, helping support children and families across the U.S.

* Caramel Apple a la Mode pancakes are available for dine-in at participating IHOP restaurants nationwide. Price and participation may vary by location. While supplies last.

ABOUT INTERNATIONAL HOUSE OF PANCAKES, LLC

For more than 62 years, IHOP has been a leader, innovator and expert in all things breakfast, any time of day. The chain offers 65 different signature, fresh, made-to-order breakfast options, a wide selection of popular lunch and dinner items, including Ultimate Steakburgers. IHOP restaurants offer guests an affordable, everyday dining experience with warm and friendly service. As of June 30, 2021, there are 1,747 IHOP restaurants around the world, including restaurants in all 50 states and the District of Columbia, Puerto Rico and Guam as well as Canada, Ecuador, India, Mexico, Pakistan, Panama and Peru. IHOP restaurants are franchised by affiliates of Glendale, Calif.-based Dine Brands Global, Inc. (NYSE: DIN).

About Children’s Miracle Network Hospitals

Children’s Miracle Network Hospitals® raises funds for 170 children’s hospitals that support the health of 10 million kids each year across the U.S. and Canada. Donations go to local hospitals to fund critical life-saving treatments and healthcare services, along with innovative research, vital pediatric medical equipment, child life services that put kids’ and families’ minds at ease during difficult hospital stays and financial assistance for families who could not otherwise afford these health services. When we improve the health of all children and allow them the opportunity to reach their full potential, we also improve our communities for years to come. Together, we can change kids’ health. Together, we can change the future. To learn about Children’s Miracle Network Hospitals and your local children’s hospital, visit cmnhospitals.org.

Candice Jacobson

IHOP Communications

[email protected]

Or

Zevenia Dennis

DeVries Global on behalf of IHOP

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Philanthropy Retail Restaurant/Bar Other Philanthropy Fund Raising Food/Beverage

MEDIA:

Logo
Logo
Photo
Photo
Kid Chef Winner, Rayaan (Photo: Business Wire)
Photo
Photo
Caramel Apple a la Mode Pancake, created by Kid Chef Winner, Rayaan (Photo: Business Wire)
Posted on

Farmmi, Inc. Prices $81 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

PR Newswire

LISHUI, China, Sept. 13, 2021 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced the pricing of an underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares (“Offering”), with gross proceeds to the Company expected to be approximately $81 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The Offering equates to 368,261,717 of the Company’s ordinary shares at a price of $0.22 per share. The pre-funded warrants shall be offered at the same price per share as the ordinary shares, less the $0.0001 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this Offering for general corporate and working capital needs and capital expenditures. The ordinary shares are trading on The Nasdaq Capital Market under the symbol “FAMI”. The closing of the Offering is expected to occur on September 15, 2021, subject to customary closing conditions.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

The Offering is being made pursuant to an effective shelf registration statement on Form F-3 (No 333-254036) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on March 16, 2021. A preliminary prospectus supplement and accompanying prospectus describing the terms of the Offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at [email protected], or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is an agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi and other agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including statements relating to the offering, including as to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/farmmi-inc-prices-81-million-underwritten-public-offering-of-ordinary-shares-and-pre-funded-warrants-to-purchase-ordinary-shares-301375207.html

SOURCE Farmmi, Inc.

Posted on

Leisure Demand Continues To Drive Hyatt’s Brand Growth In Europe

Hyatt’s diverse brand portfolio reflects sustained growth, fueled largely by its independent collection and lifestyle brands

PR Newswire

CHICAGO, Sept. 13, 2021 /PRNewswire/ — Hyatt Hotels Corporation (NYSE: H) today announced that a Hyatt affiliate has entered into six new management and franchise agreements for hotels in Europe across The Unbound Collection by Hyatt, JdV by Hyatt, Hyatt Centric, and Hyatt Regency brands, further emphasizing a growing desire from travelers, World of Hyatt members, and owners for hotels that offer unique, differentiated experiences and foster genuine connections with people and cultures.

Today’s announcement builds on Hyatt’s growth strategy to significantly expand its brand portfolio in Europe by the end of 2023 – the six new executed agreements are expected to increase Hyatt’s brand presence in France, Germany, Italy, Spain, and Switzerland. This is in addition to the recently announced planned acquisition of Apple Leisure Group (ALG), which is expected to expand Hyatt’s European brand footprint by 60 percent.

“The newly executed agreements highlight the positive strides we are making towards our growth strategy in Europe, and the new projects sit alongside a strong pipeline of Hyatt-branded hotels scheduled to open over the coming years,” said Felicity Black-Roberts, Hyatt’s vice president development, Europe. “Confidence in the hospitality sector remains high among investors, and we are delighted to collaborate with leading owners and operators who recognize the value and profitability of Hyatt’s entire brand portfolio, with an emphasis on Hyatt’s independent collections, including The Unbound Collection by Hyatt and JdV by Hyatt brands, and lifestyle brands, including Hyatt Centric. With these new deals, we are asserting our expertise in leisure destinations, reinforcing that Hyatt’s brands continue to resonate and cater to leisure travelers.”

Newly executed deals include:


The Unbound Collection by Hyatt

The Unbound Collection by Hyatt hotel in Crans-Montana, Switzerland

The luxurious boutique hotel Rhodania in the Swiss Alps is expected to join The Unbound Collection by Hyatt in 2023. The 41-room hotel is currently located right on the third tee of the famous Severiano Ballesteros golf course, approximately 4,900 feet (1,500 meters) above sea level in one of the most prestigious and well-established year-round mountain destinations in Switzerland. The region is also well known for its wealth of sporting options, including skiing, mountain biking, hiking and golfing; one of the most renowned golf tournaments played on European soil takes place in Crans-Montana each year. The hotel is expected to deliver on the brand’s mission of providing experiences that inspire unforgettable memories for guests seeking elevated yet unscripted service when they travel. Inside the hotel, the rooms and suites will be characterized by their elegant and luxurious décor. The hotel’s food and beverage outlets will offer high-quality local products and regional cuisine at both the main restaurant and the Swiss Chalet, creating unique dining experiences for worldly, independent-minded guests.

ll Tornabuoni Hotel in Florence, Italy

A Hyatt affiliate has entered into a franchise agreement with AG Group for Il Tornabuoni Hotel in Florence, which will join The Unbound Collection by Hyatt brand. The luxury boutique 62-room hotel is expected to open in October 2021 and will be the first Hyatt-branded property in Florence. The historic property on the Via de Tornabuoni will be surrounded by many high-end fashion boutiques and some of the most extraordinary tourist attractions. Guests will be able to step back in time with a climb up Giotto’s Campanile, a marbled Gothic tower that delivers spectacular views across the city, and will find the historic Ponte Vecchio, which is a Medieval bridge hosting authentic Italian jewelry shops, right at their doorstep. Carefully curated, the hotel’s interior design will truly reflect its historic roots from the Renaissance era, offering guests a story-worthy experience. References to the city’s architecture, history, nature, and food will be woven throughout the hotel’s design and amenities.


JdV by Hyatt

The Tribune Hotel in Rome, Italy

The Tribune Hotel, which is expected to join the JdV by Hyatt brand, will mark a significant and long-awaited milestone in Hyatt’s growth strategy: the introduction of the Hyatt brand to Rome. A Hyatt affiliate has entered into a franchise agreement with AG Group for the new hotel in the UNESCO World Heritage Site city. The hotel is slated to open in October 2021. Once the capital of an ancient republic and empire, Rome is known as the “Eternal City,” remaining today a political capital, religious center, and memorial to the creative imagination of the past. Located just off the Via Veneto, made famous in Federico Fellini’s film La Dolce Vita, and close to major tourist attractions, the 52-room upscale hotel will inspire playful travel through neighborhood connections. Whether guests are planning to conclude the evening in style on the hotel’s rooftop terrace with views of the Villa Borghese or head out to wander like a local through the city’s nightlife, the vibrant Tribune Hotel will welcome everyone with its socially inclusive concept in the center of Rome’s most happening neighborhood.

A JdV by Hyatt hotel in Bordeaux, France

Driving further momentum within Hyatt’s independent collections portfolio, the JdV by Hyatt brand is expected to debut its first hotel in Bordeaux, France, a city rich in architectural and cultural heritage with highlights including its famous harbor, Port de la Lune, a UNESCO World Heritage Site. A Hyatt affiliate has entered into a franchise agreement with Alboran Hotels and Hospitality for a JdV by Hyatt hotel, which is expected to open in 2022. Located in one of the most active districts of Bordeaux, the independent hotel will be a true reflection of the local neighborhood, enabling guests to immerse themselves in Bordeaux’s culture and connect with its communities. The 147-room property will feature a main restaurant and bar, where guests can enjoy regional flavors, cuisines and drinks, as well as a private rooftop speakeasy bar and terrace for unique experiences. Further thoughtful reflections of the local culture throughout the hotel will invite guests seeking vibrant and socially inclusive stays to embrace the free spirit of Bordeaux.


Hyatt Centric

Hyatt Centric Altstadt Hamburg in Hamburg, Germany

The Hyatt Centric brand will debut in Germany under a franchise agreement between a Hyatt affiliate and SV Hotel AG. Hyatt Centric Altstadt Hamburg will be located on Moenckebergstrasse, one of Hamburg’s most vibrant shopping streets. As a brand synonymous with adventure and being in the center of the action, the Hyatt Centric brand is a perfect addition to this vibrant location. In addition to securing a strong entry for the brand in Hamburg, a key international destination for leisure and business, Hyatt Centric Altstadt Hamburg is slated to open in 2025 and will be the second Hyatt-branded hotel in the city, joining Park Hyatt Hamburg. The property will feature a stunning top-floor panoramic restaurant and bar, outdoor seating, and a fitness center.


Hyatt Regency

Hyatt Regency Madrid Residence
s in Madrid, Spain

Hyatt Regency Hesperia Madrid will expand on its current hotel accommodations to include a residential component – Hyatt Regency Madrid Residences. With 22 premium apartments, the new complex will be located at Paseo de la Castellana, in the heart of the financial center of the capital and in close proximity to many international businesses, diplomatic offices and embassies. The residences will offer lush and spacious apartments, ranging from 1,000 square feet (100 square meters) to an exceptional 3,700-square-foot (350 square meter) penthouse that will feature a 1,000-square-foot (100 square meter) terrace with panoramic views of the city’s main avenue. Designed for productivity and peace of mind, guests of Hyatt Regency Madrid Residences will have access to the services and amenities at Hyatt Regency Hesperia Madrid. Guests that seek intuitive experiences and stress-free environments will find all they need to stay connected and energized at Hyatt Regency Madrid Residences.

Recent Hyatt hotel openings across Europe include:

For more information about Hyatt hotels, please visit: www.hyatt.com.

The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.

 

Cision View original content:https://www.prnewswire.com/news-releases/leisure-demand-continues-to-drive-hyatts-brand-growth-in-europe-301375205.html

SOURCE Hyatt Hotels Corporation

Posted on

Enact Announces Launch of Initial Public Offering

PR Newswire

RALEIGH, N.C., Sept. 13, 2021 /PRNewswire/ — Enact Holdings, Inc. (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today announced that it has commenced an initial public offering of 13,310,400 shares of common stock. All of the shares are being offered by the selling stockholder, Genworth Holdings, Inc. (GHI), a wholly owned subsidiary of Genworth Financial, Inc., and net proceeds from the offering will go to GHI.

The initial public offering price is expected to be between $19.00 and $20.00 per share. GHI expects to grant the underwriters a 30-day option to purchase up to an additional 1,996,560 shares of Enact’s common stock at the initial public offering price, less the underwriting discount. The shares are expected to trade on the Nasdaq Global Select Market under the ticker symbol “ACT.”

In addition to the shares being sold in the initial public offering, certain investment funds managed by Bayview Asset Management, LLC (Bayview) have agreed to purchase shares of Enact’s common stock from GHI in a concurrent private sale at a price per share equal to the initial public offering price less the underwriting discount per share. Bayview has agreed to purchase (i) 14,655,600 shares of Enact’s common stock if the initial public offering price is less than or equal to $22.00 per share; or (ii) 4,000,000 shares of our common stock if the initial public offering price is greater than $22.00 per share but less than or equal to $24.00. The concurrent private sale is contingent upon the initial public offering and subject to closing conditions, including the completion of the initial public offering at a price per share at or below $24.00. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are serving as lead book-running managers for the proposed offering.

Copies of the preliminary prospectus may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected], or by telephone at (866) 471-2526; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected], or by telephone at 1-866-803-9204.

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enact Holdings, Inc.

Enact, operating principally through its wholly owned subsidiary Genworth Mortgage Insurance Co. since 1981, is a leading U.S. private mortgage insurance provider committed to helping more people achieve the dream of homeownership. Building on a deep understanding of lenders’ businesses and a legacy of financial strength, we partner with lenders to bring best-in class service, leading underwriting expertise, and extensive risk and capital management to the mortgage process, helping to put more people in homes and keep them there. By empowering customers and their borrowers, Enact seeks to positively impact the lives of those in the communities in which it serves in a sustainable way. Enact is headquartered in Raleigh, North Carolina.

 

Cision View original content:https://www.prnewswire.com/news-releases/enact-announces-launch-of-initial-public-offering-301375202.html

SOURCE Enact Holdings, Inc.

Posted on

Genworth Announces Amendment of Registration Statement for Proposed Initial Public Offering by Enact

PR Newswire

RICHMOND, Va., Sept. 13, 2021 /PRNewswire/ — Genworth Financial, Inc. (NYSE: GNW) (Genworth, the Company) today announced that its wholly owned subsidiary, Enact Holdings, Inc. (Enact), has amended its registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the SEC) in connection with its proposed initial public offering. In that filing, Enact states the following regarding the use of proceeds:

As selling stockholder, Genworth Holdings, Inc. (GHI) will receive all net proceeds from the sale of shares of Enact’s common stock, including from any exercise by the underwriters of their option to purchase additional shares. GHI will bear the underwriting discount and pay or reimburse Enact for certain expenses attributable to the sale of Enact’s common stock, including accounting fees and certain legal fees. GHI currently intends to use net proceeds to repay its Promissory Note with AXA and partially repay other outstanding indebtedness.

Copies of the preliminary prospectus may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected], or by telephone at (866) 471-2526; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected], or by telephone at 1-866-803-9204.

A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genworth Financial

Genworth Financial, Inc. (NYSE: GNW) is a Fortune 500 insurance holding company committed to helping families achieve the dream of homeownership and address the financial challenges of aging through its leadership positions in mortgage insurance and long term care insurance. Headquartered in Richmond, Virginia, Genworth traces its roots back to 1871 and became a public company in 2004. For more information, visit genworth.com.

From time to time, Genworth releases important information via postings on its corporate website. Accordingly, investors and other interested parties are encouraged to enroll to receive automatic email alerts and Really Simple Syndication (RSS) feeds regarding new postings. Enrollment information is found under the “Investors” section of genworth.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning & include, but are not limited to, statements regarding the outlook for future business and financial performance of Genworth Financial, Inc. (Genworth) and its consolidated subsidiaries. Examples of forward-looking statements include statements the company makes relating to a potential minority IPO of Enact Holdings, Inc. and future reductions of debt. Forward-looking statements are based on management’s current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.  Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks, including those discussed at the end of this presentation, as well as in the risk factor section of Genworth’s Annual Report on Form 10-K, filed with the United States Securities and Exchange Commission (SEC) on February 26, 2021. Genworth undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.

 

Cision View original content:https://www.prnewswire.com/news-releases/genworth-announces-amendment-of-registration-statement-for-proposed-initial-public-offering-by-enact-301375200.html

SOURCE Genworth Financial, Inc.

Posted on

Medigus: Revoltz Commenced Prototype Manufacturing of its Micro-mobility Vehicle

Revoltz Model One is a micro-mobility vehicle for last mile and food delivery.

OMER, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Revoltz, its EV joint venture (19.9% owned), has begun the prototype manufacturing of its micro mobility vehicle.

The production has commenced in China together with Mr. Weijian Zhou, one of Revoltz partners. Weijian Zhou is a manufacturer of high-end scooters, E-mobility and Skiing Machines. Mr. Zhou’s operations are equipped with advanced machining and inspection facilities, an R&D center, and a Training Institute.

Revoltz recently completed the preliminary design and functional prototype of Model One, its micro-mobility vehicle for last mile and food delivery, which is designed to facilitate efficient delivery of smaller items in urban environments while maintaining low and immediate transportation costs.

A three-wheeled chassis with a wide platform design provides maximum safety for the rider as well as complete mobility in imperfect road conditions. The Model One design includes two loading surfaces, front and rear, each of which can be used flexibly with interchangeable modules, depending on the customer’s needs. The model is designed to carry two-and-a-half times the cargo of a traditional scooter.

The newly manufactured prototypes will be used by Revoltz to further advance its development and to approach potential commercial partners.

About Revoltz

Revoltz, a joint venture between Medigus, through its wholly owned subsidiary, Charging Robotics Ltd., and Amir Zaid and Weijian Zhou, the founders of EMuze, is a privately held company that designs and develops electric micro-mobility vehicles. Revoltz’s focus is developing EVs to meet the demands of commercial users and mission-specific designs, including full work day single charge, heavy-duty and rigid operations, Hop-on-Hop-off modes, off-road travel and a low cost of operation.

About Medigus

Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technologies company that is focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce, and electric vehicle markets. Medigus’ affiliations in the medical solutions arena consist of ownership in ScoutCam (OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff’s Brands and Eventer Technologies, Ltd. In the electric vehicle market, Charging Robotics, Ltd. and Revolz are also part of the Company’s portfolio of technology solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/investor-relations.

Cautionary Note Regarding Forward Looking Statements

This letter may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of Medigus’ management and its knowledge of the relevant market. Medigus has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus is using forward looking statements when it discusses Revoltz’s Model One design and functional prototype, the belief that the positive initial performance assessments of the Model One prototype reflects the innovation and engineering incorporated in its design, and that the newly manufactured prototypes will be used by Revoltz to further advance its development and to approach potential commercial partners. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus are discussed in detail in Medigus’ filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus’ securities. Nothing in this letter should be deemed to be medical or other advice of any kind.

Contact

Tali Dinar
Chief Financial Officer
+972-8-6466-880
[email protected]



Posted on

Coinbase Announces Proposed Private Offering of $1.5 Billion of Senior Notes for General Corporate Purposes Including Product Development and Potential M&A

Coinbase Announces Proposed Private Offering of $1.5 Billion of Senior Notes for General Corporate Purposes Including Product Development and Potential M&A 

Remote-First-Company/CHICAGO–(BUSINESS WIRE)–
Coinbase Global, Inc. (“Coinbase”) (Nasdaq: COIN) today announced its intention to offer, subject to market conditions and other factors, $1.5 billion aggregate principal amount of its Senior Notes due 2028 and 2031 (the “notes”) in a private offering (the “offering”). The notes will be fully and unconditionally guaranteed by Coinbase, Inc., a wholly owned subsidiary of Coinbase. The interest rate, redemption provisions, and other terms of each series of notes will be determined by negotiations between Coinbase and the initial purchasers.

This capital raise represents an opportunity to bolster our already-strong balance sheet with low-cost capital. Coinbase intends to use the net proceeds from the offering for general corporate purposes, which may include continued investments in product development, as well as potential investments in or acquisitions of other companies, products, or technologies that Coinbase may identify in the future. The closing of the offering is subject to market and other conditions.

The notes and the related guarantee will only be offered and sold by means of a private offering memorandum to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. Neither the notes nor the related guarantee have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from such registration requirements.

This announcement is neither an offer to sell nor a solicitation of an offer to buy the notes or the related guarantee and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

About Coinbase

Coinbase is building the cryptoeconomy – a more fair, accessible, efficient, and transparent financial system enabled by crypto. Coinbase started in 2012 with the radical idea that anyone, anywhere, should be able to easily and securely send and receive Bitcoin. Today, Coinbase offers a trusted and easy-to-use platform for accessing the broader cryptoeconomy.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” including, among other things, statements relating to the completion, timing, and size of the proposed offering, and the expected use of proceeds from the offering. Statements containing words such as “could,” “believe,” “expect,” “intend,” “will,” or similar expressions constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Coinbase will offer the notes or consummate the proposed offering, the final terms of the proposed offering, market conditions affecting the proposed offering, changes in plans or timing relating to the proposed offering, the anticipated use of the net proceeds of the proposed offering, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally, including the impacts of the COVID-19 pandemic. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect Coinbase’s business and financial results, please review the “Risk Factors” described in Coinbase’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed with the Securities and Exchange Commission (the “SEC”) and in Coinbase’s other filings with the SEC. Except as may be required by law, Coinbase undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release. 

Press: [email protected]

Investors: [email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Finance Software Banking

MEDIA:

Posted on

CalAmp’s LoJack Italia Launches CalAmp iOn™ Fleet Management Experience for Smart Decision Making

– Intuitive user interface streamlines track and trace fleet, asset and workforce visualizations

– Magnifies mission-critical insights to increase fleet efficiency, cost savings and safety

PR Newswire

MILAN and IRVINE, Calif., Sept. 13, 2021 /PRNewswire/ — CalAmp (Nasdaq: CAMP), a connected intelligence company helping businesses and people track, monitor and recover vital assets with real-time visibility and insights, announced today its subsidiary, LoJack® Italia, has launched CalAmp iOn™ in Italy. The fully integrated fleet and asset management solution helps transportation, industrial, government, commercial and service fleet operators reduce costs, increase operational efficiency and improve fleet safety.

Those who have worked with today’s fleet and asset management tools understand the pain of trying to run the right report or access critical data in time to drive value for their organization. Based on extensive telematics experience and research with fleet operators, CalAmp iOn delivers real-time business-critical data insights about vehicles, drivers and assets to enable more informed decisions that streamline fleet operations.

These mission critical insights enable fleet:

  • Workflow Efficiency – with intuitive dashboards, map layering and asset breadcrumb trails that provide a holistic view of an entire fleet and workforce, allowing operators to proactively manage operations from a desktop, table or mobile phone
  • Safety – with on-demand access to reports and alerts offering in-the-moment intervention to address critical issues like vehicle failures, dangerous driving behavior and collisions
  • Cost Savings – by identifying engine idling to reduce fuel costs; reducing costly repairs by using the maintenance manager; maintaining service schedules with iOn Tags™ that notify drivers when a piece of equipment has been left behind; using geofences around offices to automate time and attendance
  • Visibility – of all vital assets, road conditions, weather, traffic and more to enable smoother, more efficient and safer operational workflows

With the CalAmp iOn suite of web and mobile SaaS telematics services, fleet utility managers know exactly where their critical assets are so that they can quickly allocate these resources in the field. Because the CalAmp iOn platform blends fleet tracking with Esri® ArcGIS® insight, fleet operators will have access to accurate and essential data that can measurably improve their operations, profitability, and even save lives.

“CalAmp has decades of experience in connected intelligence technologies that improve fleet and asset management, efficiency and safety,” said Maurizio Iperti, senior vice president of LoJack EMEA and managing director of LoJack Italia. “By launching CalAmp iOn, we are excited to bring that expertise to a broad range of commercial and service fleet operators across Italy to help them make smart business decisions that will streamline their operations and drive greater market value.”

“We’ve spoken to dozens of world-class fleet and logistics teams and conducted thorough market analyses to determine how fleet managers optimize their assets, and one pain-point emerged: it takes too many clicks and it is too hard to find the data needed to make real-time decisions that improve the bottom line,” said Jeff Clark, senior vice president of product management and UX design at CalAmp. “Now we have created a streamlined and data-enriched intuitive user interface experience that fleet operators of all sizes in Italy can use to increase their operational efficiencies, bringing greater value to their customers.”

CalAmp iOn was selected by Equipment Today as one of its 2020 Contractors’ Top 50 New Products and garnered a 2021 IoT Evolution Product of the Year Award from IoT Evolution World.

For more information about CalAmp iOn by LoJack Italia, visit www.lojack.it/ion/ and learn how to transform the way you manage your fleet.

About LoJack Italia
LoJack Italia, a wholly-owned CalAmp subsidiary, is a market leader in stolen vehicle recovery and innovative automotive services in Italy and across the E.U., helping over 9 million people protect their assets and vehicles from theft. We have been active in Italy for 15 years and are undergoing a strong growth phase with more than 500,000 software and service subscribers achieved in the last 5 years. Today, LoJack Italia is leveraging CalAmp’s telematics technology to create a new level of value for the automotive, insurance, and car rental markets and their end-customers through easily accessible, innovative connected vehicle solutions. For more information, visit lojack.it or LinkedIn, Twitter, Instagram, Top Recovery, YouTube, LoJack Blog.

About CalAmp
CalAmp (Nasdaq: CAMP) is a connected intelligence company that helps people and businesses work smarter. We partner with transportation and logistics, industrial equipment, government and automotive industries to deliver insights that enable businesses to make the right decisions. Our applications, platforms and smart devices allow them to track, monitor and recover their vital assets with real-time visibility that reduces costs, maximizes productivity and improves safety. Headquartered in Irvine, California, CalAmp has been publicly traded since 1983. We have 22 million products installed and over 1.3 million software and services subscribers worldwide. For more information, visit calamp.com, or LinkedIn, Facebook, Twitter, YouTube or CalAmp Blog.

CalAmp, LoJack,


TRACKER


,


Here Comes The Bus


,


Bus Guardian


,


iOn Vision


,


CrashBoxx


 and associated logos are among the trademarks of CalAmp and/or its affiliates in the United States, certain other countries and/or the EU. Spireon acquired the LoJack® U.S. Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada. Any other trademarks or trade names mentioned are the property of their respective owners.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/calamps-lojack-italia-launches-calamp-ion-fleet-management-experience-for-smart-decision-making-301374893.html

SOURCE CalAmp

Posted on

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Interim analysis met the threshold for a high probability of clinical efficacy

Data from interim analysis support accelerated planning for the Phase 3 program

SOOTHE Phase 2b trial is on track to deliver topline results in Q4 2021

LAVAL, Quebec–(BUSINESS WIRE)–
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).

An independent statistical team reported that the predefined stringent probability threshold for clinical efficacy was met for at least one dose of BLU-5937. The following observations of the interim data were made regarding key aspects of the BLU-5937 product profile:

– At least one dose of BLU-5937 met the stringent predefined probability threshold for a clinically meaningful reduction in placebo-adjusted 24-hour cough frequency;

– Limited taste-related adverse events were observed, consistent with previous BLU-5937 trials;

– No serious adverse events were reported.

“We believe the encouraging SOOTHE Phase 2b trial interim analysis will enable us to accelerate the planning for our Phase 3 program while awaiting SOOTHE final results,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “With trial enrollment progressing as planned, we anticipate announcing topline data in the fourth quarter of 2021.”

About SOOTHE

The SOOTHE trial is a multicenter, randomized, double-blind, four-week, parallel arm, placebo-controlled Phase 2b trial evaluating three doses of BLU-5937 (12.5 mg, 50 mg and 200 mg BID) in 300 participants with refractory chronic cough. 240 participants with a baseline awake cough frequency of ≥25 awake coughs per hour are expected to be randomized across four arms (1:1:1:1) evaluating the three active doses of BLU-5937 and placebo in the main study. Treatment arms will be stratified to balance the number of participants with baseline awake cough frequency ≥45 coughs per hour across trial arms. The primary efficacy endpoint will be the placebo-adjusted change in the 24-hour cough frequency from baseline to day 28 collected with a cough recorder. An exploratory group of an additional 60 participants with a baseline awake cough frequency of ≥10 and <25 coughs per hour are expected to be randomized across 2 arms (1:1) evaluating one active dose (200 mg BID) and placebo to further investigate the effect of BLU-5937 in patients with lower cough frequency. More information about the trial is available at www.clinicaltrials.gov: NCT04678206.

About the Interim Analysis

An independent statistical team conducted the preplanned interim analysis once half of the total participants in the main trial completed their treatment period. The interim analysis was performed for administrative purposes and has no impact on the design or future conduct of the SOOTHE trial. Trial participants will continue to be enrolled and followed to trial completion.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options specifically targeting the burden of pruritus in patients with AD.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” “possible,” “projects,” “plans,” and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health’s control. Such statements include, but are not limited to, the potential of BLU-5937 to successfully treat chronic cough, chronic pruritus and other hypersensitization-related disorders, BELLUS Health’s expectations related to its preclinical studies and clinical trials, including the design and timing of its Phase 2b clinical trial of BLU-5937 in RCC and its Phase 2a clinical trial of BLU-5937 in chronic pruritus associated with AD, including the timing and outcome of interactions with regulatory agencies, the potential activity and tolerability profile, selectivity, potency and other characteristics of BLU-5937, including as compared to other competitor candidates, the commercial potential of BLU-5937, including with respect to patient population, pricing and labeling, BELLUS Health’s financial position, and the potential applicability of BLU-5937 and BELLUS Health’s P2X3 platform to treat other disorders. Risk factors that may affect BELLUS Health’s future results include but are not limited to: the benefits and impact on label of its enrichment strategy, estimates and projections regarding the size and opportunity of the addressable RCC market for BLU-5937, the ability to expand and develop its project pipeline, the ability to obtain adequate financing, the ability of BELLUS Health to maintain its rights to intellectual property and obtain adequate protection of future products through such intellectual property, the impact of general economic conditions, general conditions in the pharmaceutical industry, the impact of the COVID-19 pandemic on BELLUS Health’s operations, plans and prospects, including to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights , achievement of forecasted preclinical study and clinical trial milestones, reliance on third parties to conduct preclinical studies and clinical trials for BLU-5937, the ability of the interim analysis to predict the final results of the SOOTHE trial, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health’s product candidate’s development process and its market size and commercial value are dependent upon a number of factors. Moreover, BELLUS Health’s growth and future prospects are mainly dependent on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate BLU-5937 and other products. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health’s public filings with the Canadian securities regulatory authorities, including, but not limited to, its Annual Information Form, and the United States Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 40-F, for further risk factors that might affect BELLUS Health and its business.

FOR MORE INFORMATION:

Ramzi Benamar

Chief Financial Officer

[email protected]

Media:

Julia Deutsch

Solebury Trout

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Other Science Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

NextGen Healthcare Welcomes Highly Regarded Healthcare Executive Darnell Dent to Director Slate for 2021 Annual Meeting

NextGen Healthcare Welcomes Highly Regarded Healthcare Executive Darnell Dent to Director Slate for 2021 Annual Meeting

Brings Wealth of Experience Growing Managed Care Health Plan Companies and Leveraging Technology to Drive Cost Efficiencies and Revenue Growth

ATLANTA–(BUSINESS WIRE)–
NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced that Darnell Dent has joined the Company’s slate of director nominees for the 2021 Annual Meeting of Shareholders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005261/en/

NextGen Healthcare Board Nominee, Darnell Dent (Photo: Business Wire)

NextGen Healthcare Board Nominee, Darnell Dent (Photo: Business Wire)

Dent has nearly three decades of experience leading managed healthcare plan companies, including serving as Chief Executive Officer of FirstCare Health Plans. He is a current strategic advisor to Softheon, Inc., which provides healthcare payors, providers and government agencies with SaaS-based integrated technology solutions to help them reduce costs, increase efficiencies and grow revenues.

“Darnell brings a record of success leading managed healthcare companies and first-hand knowledge of the important role that technology-enabled solutions play in improving the lives of patients and providers,” said Jeffrey Margolis, Chair of the NextGen Healthcare Board of Directors. “His broad understanding of various benefit and payment mechanisms across the healthcare industry and his NACD governance credentials will be of great benefit to NextGen Healthcare as we extend our market solutions and evolve our capabilities to make healthcare better for everyone.”

Dent said, “NextGen Healthcare shares my belief that innovative healthcare technology is key to improving outcomes and advancing healthcare equity in all practices and communities. I look forward to working with the Board and management team to ensure that the important investments NextGen Healthcare is making continue to build on the Company’s momentum and its record in transforming ambulatory care.”

NextGen Healthcare’s Slate of Director Nominees for the 2021 Annual Meeting

Dent’s nomination follows NextGen Healthcare’s prior announcement that the Board intends to add two additional nominees to the Company’s director slate in advance of the Annual Meeting. The NextGen Healthcare Board is continuing to make good progress on the selection of a new CEO and expects that individual to be a valuable addition to the Board. The CEO is expected to be appointed by the Company before the Annual Meeting and included on the Company’s director slate.

Of the Company’s current slate of eight director nominees, four (or 50%) have been added in the past four years and are diverse across race and gender. Upon the CEO’s appointment to the Board, five of the Company’s directors (or more than 50%) will have been added in the past four years.

The Company’s current slate of independent director nominees includes:

  • Craig A. Barbarosh
  • George H. Bristol
  • Darnell Dent
  • Julie D. Klapstein
  • Jeffrey H. Margolis
  • Dr. Geraldine McGinty
  • Morris Panner
  • Dr. Pamela Puryear

The NextGen Healthcare Board of Directors recommends that shareholders vote “FOR” the election of each of NextGen Healthcare’s highly qualified director nominees and “FOR” ALL other proposals listed on the WHITE proxy card, including the proposals to reincorporate the Company into Delaware and eliminate cumulative voting. Approving the reincorporation and cumulative voting proposals will effectively result in giving NextGen Healthcare shareholders the opportunity to vote “FOR” ALL candidates on the NextGen Healthcare slate of director nominees under plurality voting, which is a “one share, one vote” standard, and the nine nominees with the most votes will be elected.

About Darnell Dent

Dent is Founder and Principal of Dent Advisory Services, LLC, a management consulting and governance services company. He serves as a strategic advisor to Softheon, Inc., a leading provider of cloud-based health insurance exchange (“HIX” or “marketplace”) technology. He serves in a similar capacity for Virgin Pulse, part of Sir Richard Branson’s Virgin Group, a global provider of employee well-being solutions, including integrated health, well-being, safety, benefits navigation and care guidance.

Previously, Dent was President and CEO of FirstCare Health Plans, a provider-owned health plan acquired by Baylor Scott & White Health System. Prior to that, he served as Chief Business Development Officer at the University of Pittsburgh Medical Center Health Plan. Earlier he held senior executive roles at United HealthCare, Community Health Plan of Washington, Health Net and Lincoln National Corporation.

He is a National Association of Corporate Directors (NACD) Board Leadership Fellow and serves as a director on the Board of the Texas TriCities Chapter. He is past Chair of the Association of Community Affiliated Health Plans, which plans serve more than seventeen million enrollees, representing nearly half of all individuals enrolled in Medicaid managed care plans, and past Chair of the Texas Association of Community Health Plans. Previously, he served as a Board member for Adaptis, a healthcare IT company.

Dent earned his bachelor’s degree from Norfolk State University in Psychology and his MPA from Pepperdine University in Public Administration. He served in the United States Marine Corps as an officer attaining the rank of Captain.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Certain Information Concerning the Participants

NextGen Healthcare has filed a revised preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”), together with the associated WHITE proxy card, in connection with the solicitation of proxies for NextGen Healthcare’s 2021 Annual Meeting of Shareholders (the “Preliminary Proxy Statement”). WE URGE SHAREHOLDERS TO READ THE PRELIMINARY PROXY STATEMENT AND THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENTS) WHEN AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS THAT NEXTGEN HEALTHCARE WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. NextGen Healthcare, certain of its directors and executive officers will be participants in the solicitation of proxies from shareholders in respect of the 2021 Annual Meeting. Information regarding the names of NextGen Healthcare’s directors and executive officers and their respective interests in NextGen Healthcare by security holdings or otherwise are set forth in the Preliminary Proxy Statement. To the extent holdings of such participants in NextGen Healthcare’s securities are not reported, or have changed since the amounts described, in the Preliminary Proxy Statement, such changes will be reflected in the Definitive Proxy Statement or on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of NextGen Healthcare’s Board of Directors for election at the 2021 Annual Meeting are included in the Preliminary Proxy Statement.

Shareholders will be able to obtain, free of charge, copies of the applicable proxy statement, any amendments or supplements thereto and any other documents when filed by NextGen Healthcare with the SEC in connection with the Annual Meeting at the SEC’s website (http://www.sec.gov), at NextGen Healthcare’s website (https://investor.nextgen.com), by emailing [email protected] or by calling MacKenzie Partners at (800) 322-2885.

Forward Looking Statements

This communication may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events including but not limited to the COVID-19 pandemic, developments in the healthcare sector and regulatory framework, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: volatility and uncertainty in the global economy, financial markets and on our customers in light of the continuing COVID-19 pandemic, including the potential (i) slowdown or shutdown of preventive and elective medical procedures, (ii) delay in the contracting for additional products and services by our customers and (iii) delay in the sales cycle for new customers; a determination by the jury that the Company has liability in litigation advanced by a former director and shareholder; the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company’s ability or inability to attract and retain qualified personnel; the impact of any proxy contest at the 2021 Annual Meeting of Shareholders; possible regulation of the Company’s software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods’ financial statements; disruptions caused by acquisitions of companies, products, or technologies; the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect our financial condition and results of operations; and general economic conditions. A significant portion of the Company’s quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company’s revenues and operating results are very difficult to forecast. A major portion of the Company’s costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company’s period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact

Tami Stegmaier

(949) 237-6083

[email protected]

Barrett Golden / Sharon Stern

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

[email protected]

Investor Relations Contact

Matthew Scalo

(415) 370-9202

[email protected]

Laurie Connell

[email protected]

(212) 378-7071

Daniel Burch

[email protected]

(212) 929-5748

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Software Practice Management Managed Care General Health Health Data Management Technology Other Health

MEDIA:

Logo
Logo
Photo
Photo
NextGen Healthcare Board Nominee, Darnell Dent (Photo: Business Wire)